Under construction – not a live service

Skip to content

Frontlight Research

Institution

University Hospital Brno

Brno, CzechiaEU-13 widening countryWebsite

Also known as: Fakultní Nemocnice Brno

245running trials
113closed trials

Running trials

Not yet recruiting
Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis
2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source
Not yet recruiting
A study to compare heart failure medicines in one combined pill with usual care.
2026-526510-90-00· Phase 3· Institut De Recherches Internationales Servier IRIS· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure
NCT07584967· Phase 2· AnaCardio AB· Source
Recruiting
A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source
Recruiting
Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source
Recruiting
Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
NCT07672769· Phase 2· Faron Pharmaceuticals Ltd· Source
Recruiting
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
2026-526654-14-01· Phase 3· Janssen Cilag International· Source
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Takeda· Source
Recruiting
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
NCT07665450· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200· Phase 3· Incyte Corporation· Source
Not yet recruiting
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD
2026-525216-34-00· Phase 2· Expedition Therapeutics Inc.· Source
Not yet recruiting
Effect of faecal microbiota transplant on the expression of autism spectrum disorder core symptoms in children – open-label phase II clinical trial (FMT-PAS)
2025-524673-16-00· Phase 2· Masarykova Univerzita· Source
Recruiting
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729· Phase 3· Charite University, Berlin, Germany· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
2025-525105-20-00· Phase 1/2· AbbVie Deutschland GmbH & Co. KG· Source
Not yet recruiting
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
2026-525883-17-00· Phase 3· Genmab A/S· Source
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma
NCT07532265· Phase 2· Kinaset Therapeutics Inc· Source
Recruiting
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
NCT07516951· Phase 2· Chiesi Farmaceutici S.p.A.· Source
Recruiting
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
NCT07630974· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
2025-523815-12-00· Phase 3· Janssen Cilag International· Source
Recruiting
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
NCT07284602· Phase 3· PureTech· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· Phase 3· Hoffmann-La Roche· Source
Enrolling by invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152· Phase 3· Immuneering Corporation· Source
Recruiting
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
NCT07024706· Phase 2· AstraZeneca· Source
Recruiting
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952· Phase 3· Bayer· Source
Not yet recruiting
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year
2025-521590-13-00· Phase 3· Janssen Cilag International· Source
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Recruiting
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
NCT07342478· Phase 3· Newave Pharmaceutical Inc· Source
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270· Phase 3· Genmab· Source
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source
Recruiting
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
NCT07456033· Phase 3· GlaxoSmithKline· Source
Recruiting
Maridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy (MARITIME-OSA-1)
2025-522703-14-00· Phase 3· Amgen Inc.· Source
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Maridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea not on Positive Airway Pressure Therapy (MARITIME-OSA-2)
2025-522699-94-00· Phase 3· Amgen Inc.· Source
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231· Phase 3· BeOne Medicines· Source
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292· Phase 3· Sanofi· Source
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07222761· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809· Phase 3· AstraZeneca· Source
Recruiting
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
NCT06932562· Phase 3· European Myeloma Network B.V.· Source
Active, not recruiting
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT07225686· Phase 3· Amgen· Source
Recruiting
Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
2025-520982-39-00· Phase 3· Universita Degli Studi Di Milano Bicocca· Source
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691· Janssen Research & Development, LLC· Source

Showing 50 of 245.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Childhood cancers20 recruiting
Multiple myeloma14 recruiting
Heart failure11 recruiting
Acute lymphoblastic leukaemia9 recruiting
Chronic lymphocytic leukaemia9 recruiting
Crohn's disease7 recruiting
Ovarian cancer7 recruiting
Myeloproliferative neoplasms6 recruiting
Acute myeloid leukaemia5 recruiting
Obesity5 recruiting
Lung cancer4 recruiting
Multiple sclerosis4 recruiting
Myelodysplastic syndromes4 recruiting
Pancreatic cancer4 recruiting
Ulcerative colitis4 recruiting
Asthma3 recruiting
CIDP (chronic inflammatory demyelinating polyneuropathy)3 recruiting
Haemophilia3 recruiting
Immune thrombocytopenia (ITP)3 recruiting
Mantle cell lymphoma3 recruiting
Chronic myeloid leukaemia2 recruiting
Diffuse large B-cell lymphoma2 recruiting
Endometrial cancer2 recruiting
Follicular lymphoma2 recruiting
Idiopathic pulmonary fibrosis2 recruiting
Myasthenia gravis2 recruiting
Neuroblastoma2 recruiting
Obstructive sleep apnoea2 recruiting
Prostate cancer2 recruiting
Sarcoma2 recruiting
Alopecia areata1 recruiting
Ankylosing spondylitis1 recruiting
Aortic stenosis1 recruiting
Atrial fibrillation1 recruiting
Autism1 recruiting
Cervical cancer1 recruiting
Colorectal cancer1 recruiting
COPD1 recruiting
Cystic fibrosis1 recruiting
Down syndrome1 recruiting
Familial hypercholesterolaemia1 recruiting
Fatty liver disease (MASLD/MASH)1 recruiting
Head and neck cancer1 recruiting
High blood pressure1 recruiting
Kidney cancer1 recruiting
Liver and biliary tract cancer1 recruiting
Metastatic breast cancer1 recruiting
Psoriasis1 recruiting
Psoriatic arthritis1 recruiting
Pulmonary arterial hypertension1 recruiting
Systemic sclerosis (scleroderma)1 recruiting

Closed trials

Completed
A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis
NCT07222189· Phase 2· Sanofi-Aventis Recherche & Developpement· Source
Completed
Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection
2024-519856-94-00· Phase 2· Biomx Ltd.· Source
Active, not recruiting
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567· Phase 1/2· GlaxoSmithKline· Source
Completed
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
NCT06529419· Phase 2· AstraZeneca· Source
Completed
A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
2023-508736-62-00· Phase 2· Cardurion Pharmaceuticals Inc.· Source
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575· Phase 3· Jazz Pharmaceuticals· Source
Completed
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source
Active, not recruiting
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128· Phase 3· Sanofi· Source
Recruiting
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297· Phase 3· X4 Pharmaceuticals· Source
Completed
A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure
NCT06299826· Phase 2· AstraZeneca· Source
Completed
A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1
NCT05870748· Phase 2· Sutro Biopharma Inc.· Source
Terminated
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
NCT06237309· Phase 2· Regeneron Pharmaceuticals· Source
Completed
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
NCT05813288· Phase 3· Areteia Therapeutics Inc.· Source
Completed
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
NCT06119217· Phase 2· Trishula Therapeutics, Inc.· Source
Completed
A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)
2023-509472-42-00· Phase 3· Celgene International II S.a.r.l.· Source
Completed
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
NCT06215586· Phase 2· Cardurion Pharmaceuticals, Inc.· Source
Completed
A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with moderate to severe endometriosis-related pain
2022-501310-57-00· Phase 2· Organon LLC· Source
Active, not recruiting
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
NCT05970172· Phase 3· Astellas Pharma Global Development, Inc.· Source
Active, not recruiting
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632· Phase 2· Pfizer· Source
Completed
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
NCT06017609· Phase 2· Shionogi Inc.· Source
Completed
Early Detection of HCV in Injection Drug Users
NCT06431945· Institute of Health Information and Statistics of the Czech Republic· Source
Terminated
IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
NCT06139328· Phase 2· Boehringer Ingelheim· Source
Completed
Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).
NCT06264674· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy
2022-502208-64-00· Phase 2· Chiesi Farmaceutici S.p.A.· Source
Terminated
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source
Active, not recruiting
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806· Phase 3· Celgene· Source
Completed
A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)
2022-502057-33-00· Phase 1/2· Sanofi-Aventis Recherche & Developpement· Source
Completed
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
2022-502196-31-00· Phase 2/3· Kartos Therapeutics Inc.· Source
Completed
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
NCT05952869· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa
2022-502921-16-00· Phase 4· Swedish Orphan Biovitrum AB (publ)· Source
Completed
A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly with efanesoctocog alfa.
2022-500275-31-00· Phase 3· Swedish Orphan Biovitrum AB (publ)· Source
Active, not recruiting
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566· Phase 3· Amgen· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
NCT05562466· Phase 3· Novartis Pharmaceuticals· Source
Completed
A study of efficacy and safety of various treatments in participants with idiopathic pulmonary fibrosis (IPF)
2023-508729-28-00· Phase 2· Novartis Pharma AG· Source
Completed
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· Phase 3· Janssen Research & Development, LLC· Source
Completed
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
NCT05742802· Phase 3· AstraZeneca· Source
Completed
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
2024-517612-29-00· Phase 4· The Brigham And Women’s Hospital Inc.· Source
Completed
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)
NCT05349721· Phase 2· PTC Therapeutics Inc.· Source
Terminated
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT05592275· Phase 2· Eli Lilly and Company· Source
Completed
Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)
NCT05429502· Phase 1/2· Novartis Pharma AG· Source
Active, not recruiting
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
NCT05469737· Phase 2/3· Bristol-Myers Squibb· Source
Completed
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke
NCT05643573· Phase 3· Bayer AG· Source
Completed
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
NCT05560646· Phase 2· Organon and Co· Source
Active, not recruiting
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
NCT05206357· Phase 1· Genmab· Source
Completed
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
NCT05388760· Phase 2· LEO Pharma· Source
Completed
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
NCT05398263· Phase 3· AstraZeneca AB· Source
Completed
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
NCT05243680· Phase 3· GlaxoSmithKline· Source
Completed
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumours
2024-511071-16-00· Phase 1· Glaxosmithkline Research & Development Limited· Source

Showing 50 of 113.

Trial sites

2030048 - Fakultní Nemocnice Brno1 trial
Brno University Hospital6 trials
Fakultni nemocnice Brno278 trials
Fakultní nemocnice Brno, Dětská nemocnice - Pediatrická klinika0 trials
Fakultní Nemocnice Brno - D?tská Nemocnice0 trials
Fakultni Nemocnice Brno /ID# 1281761 trial
Fakultni Nemocnice Brno /ID# 1540190 trials
Fakultni Nemocnice Brno /ID# 1592471 trial
Fakultní nemocnice Brno - Interní gastroenterologická klinika0 trials
Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika1 trial
Fakultní nemocnice Brno - Interní kardiologická klinika1 trial
Fakultní Nemocnice Brno - Jihlavská /ID# 2045120 trials
Fakultní Nemocnice Brno - Jihlavská /ID# 2148070 trials
Fakultní Nemocnice Brno - Jihlavská /ID# 2209591 trial
Fakultní Nemocnice Brno - Jihlavská /ID# 2213510 trials
Fakultní Nemocnice Brno - Jihlavská /ID# 2259530 trials
Fakultní Nemocnice Brno - Jihlavská /ID# 2399560 trials
Fakultni Nemocnice Brno - Jihlavska /ID# 2426830 trials
Fakultni Nemocnice Brno - Jihlavska /ID# 2456890 trials
Fakultni Nemocnice Brno - Jihlavska /ID# 2605710 trials
Fakultní Nemocnice Brno - Jihlavská /ID# 2683511 trial
Fakultní Nemocnice Brno - Obilní Trh /ID# 2694010 trials
Fakultni nemocnice Brno (Site 0404)0 trials
Fakultní Nemocnice Brno (Site 1003)0 trials
Gynekologicko-porodnická klinika, Fakultni nemocnice Brno0 trials
The University Hospital Brno2 trials
University Hospital Brno21 trials
University Hospital Brno, Department of Medecine Cardiology1 trial
University Hospital Brno - Dept. of Pediatric Neurology0 trials
Fakultni nemocnice Brno0 trials
Fakultni Nemocnice Brno22 trials
Fakultni Nemocnice Brno22 trials

Conditions

Diseases this institution publishes on or runs trials for.

Multiple myeloma32 works · 38 trials
Chronic lymphocytic leukaemia20 works · 21 trials
Chronic myeloid leukaemia15 works · 5 trials
Haemophilia7 works · 8 trials
Follicular lymphoma5 works · 6 trials

Institution data: ROR 00qq1fp34 (CC0-1.0)Updated 10 Nov 2026

Report an error